OTC Markets OTCPK - Delayed Quote USD

GlobeStar Therapeutics Corporation (GSTC)

Compare
0.0003 0.0000 (0.00%)
At close: 1:29 PM EST
Loading Chart for GSTC
DELL
  • Previous Close 0.0003
  • Open 0.0003
  • Bid 0.0002 x --
  • Ask 0.0003 x --
  • Day's Range 0.0003 - 0.0003
  • 52 Week Range 0.0002 - 0.0025
  • Volume 14,444
  • Avg. Volume 12,038,157
  • Market Cap (intraday) 372,333
  • Beta (5Y Monthly) 1.61
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in Richland, Washington.

www.globestartherapeutics.com

--

Full Time Employees

September 30

Fiscal Year Ends

Recent News: GSTC

View More

Performance Overview: GSTC

Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

GSTC
66.67%
S&P 500
25.15%

1-Year Return

GSTC
76.92%
S&P 500
31.54%

3-Year Return

GSTC
98.29%
S&P 500
27.06%

5-Year Return

GSTC
91.89%
S&P 500
92.34%

Compare To: GSTC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GSTC

View More

Valuation Measures

Annual
As of 11/21/2024
  • Market Cap

    372.33k

  • Enterprise Value

    702.47k

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -919.3k

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    41

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: GSTC

View More

Company Insights: GSTC

Research Reports: GSTC

View More

People Also Watch